Shares of Dexcom fell 9% in extended trading on Thursday after the company released third-quarter results that beat analysts’ expectations but showed a decline in U.S. revenue year over year.
Here’s what the company reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG:
- Earnings per share: 45 cents adjusted vs. 43 cents expected
- Revenue: $994 million vs. $990 million expected
The company’s revenue increased 2% to $994.2 million from $975 million a year earlier. Dexcom’s U.S. revenue declined 2% from $713.6 million the prior year. The company reported net income of $134.6 million, or 34 cents per share, up from $120.7 million, or 29 cents per share, in the same period last year.
Dexcom offers a suite of tools such as continuous glucose monitors, or CGMs, for patients who have been diagnosed with diabetes. In August, it launched its first over-the-counter productcalled Stelo, which is intended for …